Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Transplant Cell Ther. 2021 Dec 4;28(2):73.e1–73.e9. doi: 10.1016/j.jtct.2021.11.019

Figure 4. Analysis of the impact of pretreatment and post treatment factors on event-free and overall survival.

Figure 4.

A. Univariate analyses of event-free survival (EFS) and overall survival (OS) performed by fitting Cox regression models. Higher pre-infusion disease burden (≥5% blasts) was significantly associated with worse EFS and OS (P = 0.0176 and 0.0034, respectively). Severe CRS and antigen-directed pre-treatment were also associated with worse OS (P = 0.0047 and 0.0403, respectively) but had no impact on EFS. B. Multivariate analysis of EFS and OS, including risk factors with univariate P values less than or equal to 0.20. Higher pre-infusion disease (≥5% blasts) burden remained significantly associated with poorer EFS (P = 0.0380) and OS (P = 0.0148). EFS: date from infusion to first event (NR at week 4 evaluation, relapse [recurrent detectable disease, including MRD-positive cases], or death; patients who underwent HCT before one of these events were censored at the time of HCT). OS: date from infusion to date of death.